Date	Period	Revenue/Estimate	Earnings Call
--	2026/Q1	-- / 367.292M	--
--	2025/Q4	-- / 425.446M	--
Dec 5, 2024	2025/Q3	354.653M / 347.720M	--
Sep 5, 2024	2025/Q2	316.253M / 303.740M	--
May 29, 2024	2025/Q1	335.112M / 333.008M	--

DatePeriodRevenue/EstimateEarnings Call

--2026/Q1-- / 367.292M--

--2025/Q4-- / 425.446M--

Dec 5, 20242025/Q3354.653M / 347.720M--

Sep 5, 20242025/Q2316.253M / 303.740M--

May 29, 20242025/Q1335.112M / 333.008M--

Unlock Free Earnings Estimates

Open Account

UiPath Earnings Reports

UiPath | 10-Q: Q3 2025 Earnings Report

Dec 9, 2024 13:16 ET

UiPath | 8-K: UiPath Reports Third Quarter Fiscal 2025 Financial Results

Dec 5, 2024 16:21 ET

UiPath | 10-Q: Q2 2025 Earnings Report

Sep 6, 2024 17:15 ET

UiPath | 8-K: UiPath Reports Second Quarter Fiscal 2025 Financial Results

Sep 5, 2024 16:28 ET

Trending US Stocks

Symbol Mini Chart % Chg

Collegium Pharmaceutical

Halozyme Therapeutics

Unlock the Full List

Analysis

Analyst Rating

Updated: Dec 31, 2024

Hold

Buy
11.11%
Hold
83.33%
Sell
5.56%

Price Target

No Data

Investment Theme

Robotics

Intraday+0.17%

Artificial Intelligence

Intraday-0.29%

ARK Portfolio

Intraday-0.33%